eAppendix 1. Information Provided to Stakeholders at the Beginning of the Qualitative Interview to Provide Context for the Noninferiority Pilot Clinical Trial Using an Early Enrollment Approach
eTable. Characteristics of Investigator, Coordinator, and IRB Representative Stakeholders
eAppendix 2. Responses to Online Survey 1
eAppendix 3. Advance Informed Consent Form Text
eAppendix 4. Responses to Online Survey 2
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Corneli A, Calvert SB, Powers JH, et al. Consensus on Language for Advance Informed Consent in Health Care–Associated Pneumonia Clinical Trials Using a Delphi Process. JAMA Netw Open. 2020;3(5):e205435. doi:10.1001/jamanetworkopen.2020.5435
What information do key stakeholders want in informed consent forms for noninferiority clinical trials on hospital-acquired and/or ventilator-associated bacterial pneumonia, and how should such information be described?
In this Delphi study of 52 key stakeholders (patients at risk of pneumonia, caregivers, representatives of institutional review boards, investigators, and study coordinators), consensus was reached on how to describe reassurances on patient health and treatment, a rationale for advance consent and early enrollment, and noninferiority.
Results of this study suggest that inclusion of information on these concepts in informed consent forms may help potential participants make informed decisions about participating in noninferiority trials of health care–associated pneumonia treatment.
Information to be included in advance informed consent forms for health care–associated pneumonia treatment trials remains to be determined.
To identify and determine how to describe information to be included in an advance informed consent form for an early-enrollment noninferiority hospital-acquired and/or ventilator-associated bacterial pneumonia (HABP/VABP) clinical trial.
Design, Setting, and Participants
A Delphi consensus process with stakeholders in HABP/VABP clinical trials was conducted using qualitative semistructured telephone interviews from June to August 2016, followed by 2 online surveys, the first from April to May 2017, and the second from September to October 2017. All stakeholders who participated in the interview were invited to participate in the first survey. Stakeholders who participated in the first survey were invited to participate in the second survey. Stakeholders were patients at risk of pneumonia, caregivers, representatives of institutional review boards, investigators, and study coordinators.
Main Outcomes and Measures
Description and consensus of information to be included in advance informed consent forms for early enrollment in noninferiority HABP/VABP clinical trials.
Suggestions from 52 stakeholders about what key informed consent concepts to include and how to explain them were used to create 3 categories to be included in an advance consent form: (1) reassurances on patient health and treatment, (2) rationale for advance consent and early enrollment, and (3) an explanation of noninferiority. At the end of the Delphi process, at least 80% consensus was reached among the 40 stakeholders who participated in the second online survey on each of the statements to include in the proposed consent text. Throughout the process, however, describing and reaching consensus on statements about noninferiority was more problematic than the other categories.
Conclusions and Relevance
The stakeholders endorsed consent language to be used in combination with a strategy for enrolling patients at highest risk for pneumonia before infection onset. Data-driven consent language may help potential participants make informed decisions about their involvement in clinical research and improve enrollment rates, which are necessary to evaluate new treatments and improve patient care. The proposed consent language may be adapted for other trials using an early enrollment strategy and for noninferiority trials.
In response to difficulties in recruiting patients for clinical trials in hospital-acquired and/or ventilator-associated bacterial pneumonia (HABP/VABP),1-5 the Clinical Trials Transformation Initiative (CTTI), a public-private partnership cofounded by the US Food and Drug Administration (FDA) and Duke University, Durham, North Carolina, developed a novel early enrollment strategy as part of its portfolio of projects in antibacterial drug development.6 With this strategy, patients at risk for hospital-acquired pneumonia consent to monitoring by study staff in advance of developing pneumonia. If these patients subsequently develop HABP/VABP, they are randomly assigned to receive an investigational or comparator antibiotic. Although obtaining advance consent for treatment of potential complications that require immediate care is feasible,7 enrolling patients early into clinical trials is uncommon. Knowledge about appropriate information to include in advance consent forms for pneumonia treatment trials remains to be determined, particularly for noninferiority trials.8
Previous CTTI research suggested that key stakeholders find an early enrollment strategy using advance consent in pneumonia antibiotic trials to be acceptable.9 As a component of that research, CTTI also engaged these stakeholders to identify, describe, and reach consensus on essential concepts to be included in an advance consent form for an early-enrollment, noninferiority HABP/VABP clinical trial. We describe here the development of the proposed text for the advance consent form, together with supporting information.
We engaged 5 stakeholder groups in the research: patients at risk for pneumonia, caregivers of patients at risk for pneumonia, investigators, study coordinators, and representatives of institutional review boards (IRBs). Information on stakeholder recruitment and selection has been reported.9 We used a Delphi consensus process10 to identify information to be included in an advance consent form and how to describe that information. We explained to stakeholders that hospitalized patients who were identified to be at risk for pneumonia would be asked to consent to being monitored by study staff to determine if they develop HABP/VABP, and randomly assigned to receive 1 of 2 antibiotics if they develop HABP/VABP. The antibiotics were imipenem, an FDA-approved antibiotic for lower respiratory tract infection, and meropenem, an antibiotic approved for other serious infections and commonly used off- label for treating pneumonia. This study followed the Standards for Reporting Qualitative Research (SRQR) reporting guideline for qualitative studies.
As the first step in the Delphi process, we conducted qualitative, semistructured telephone interviews. The interviewer provided stakeholders with an overview of the proposed noninferiority trial and early enrollment strategy. The interviewer also described the study antibiotics and explained to patients and caregivers that the study hypothesis was that meropenem may not work as effectively as imipenem in the treatment of pneumonia but may have fewer adverse effects. (eAppendix 1 in the Supplement includes the study overview provided to all stakeholders.) Table 1 lists the initial and follow-up topics explored with each stakeholder group. The initial questions asked stakeholders to describe essential information that should be provided in an advance consent form and how to explain that information. The follow-up probes solicited stakeholders’ suggestions on how to explain certain topics, if not initially mentioned. We included the follow-up topics because (1) we expected the need to describe these areas in the advance consent form and wanted stakeholder feedback on how best to explain them, and (2) research has shown that the purpose of noninferiority trials (one of the probed topics) is typically not described in consent documents.8
We analyzed the qualitative data using applied thematic analysis.11 We first identified the most common essential concepts that stakeholders mentioned and how to describe them before the interviewer probing. Next, we thematically combined those responses with the probed responses on how to explain essential concepts to identify the most common suggestions for describing the concepts. We grouped these suggestions into larger consent categories, focusing on categories that go beyond the Common Rule12 elements of informed consent (eg, risks) and that the study team believed should be explained in an advance consent form (ie, noninferiority trials). The study team then drafted consent form text for these categories, taking into consideration stakeholders’ suggestions for explaining essential information.
We then conducted 2 rounds of online surveys with open-ended and closed-ended questions to assess the importance of the consent text and to reach consensus on the advance consent language. All stakeholders who participated in the interviews were invited to participate in the first survey. During the first survey, we summarized the qualitative descriptive findings from the interviews, then presented the draft consent form text for explaining each category. We informed stakeholders that our goal was to include language in the advance consent form that would be easy for patients to understand and help patients make an informed decision about participating in a noninferiority trial that uses an early enrollment strategy. We also told stakeholders that we wanted to provide concise explanations. Stakeholders reviewed the descriptive findings from the interviews and classified each statement (or group of statements) in the draft consent form text as (1) “important: remain as is,” (2) “important: but changes needed,” or (3) “unimportant: remove.” We asked stakeholders to suggest a revision if they chose response option 2 and provide a rationale if they chose option 3.
We analyzed the open-ended responses to the first survey by grouping and summarizing similar answers; we used response frequencies to assess the closed-ended responses. We used stakeholder feedback from the first survey to modify the draft consent text, and we prepared the second survey to obtain stakeholder feedback on the modified text. Only stakeholders who participated in the first survey were invited to participate in the second survey. During the second survey, stakeholders reviewed the descriptive findings from the first survey and provided feedback on the revised consent form text. They classified each statement in the draft text (or group of statements) as (1) “important: should remain” or (2) “unimportant: remove.” Stakeholders were asked to give a rationale for the removal of sentences; they could also provide overall comments for each statement or group of statements. We then reviewed the responses, using the same methods described previously, and finalized the consent text.
The Duke University Health System Institutional Review Board determined that this study meets the criteria for a declaration of exemption from further institutional review board review as described in 45 CFR 46.101(b), 45 CFR 46.102 (f), or 45 CFR 46.102 (d), and satisfies the Privacy Rule as described in 45 CFR 164.512(i).
We interviewed 52 stakeholders from June to August 2016, including 18 patients at risk of HABP/VABP and 12 caregivers of patients at risk for HABP/VABP. More than half of the patients had a bachelor’s degree or higher (10 of 18 [56%]), and all caregivers had at least a high school education. Stakeholders also included 7 investigators who conduct research on pneumonia, 5 study coordinators of pneumonia or intensive care unit–based clinical research, and 10 IRB representatives (Table 2; eTable in the Supplement).
The first online survey was conducted in April and May 2017, with a response rate of 79% (n = 41), including 14 patients, 10 caregivers, 5 investigators, 4 study coordinators, and 8 IRB representatives. The second online survey was conducted from September to October 2017, with a response rate of 98% (n = 40), including 14 patients, 9 caregivers, 5 investigators, 4 study coordinators, and 8 IRB representatives.
We identified 3 concepts that stakeholders stated were essential to describe in an advance consent form: (1) reassurances about patient health and treatment, (2) reasons for enrolling early, and (3) information about study antibiotics. We placed stakeholders’ suggestions about how to explain these concepts into 3 further categories for inclusion in an advance consent form: (1) reassurances on patient health and treatment, including information about study antibiotics, (2) a rationale for advance consent and early enrollment, and (3) an explanation of noninferiority. We included an explanation of noninferiority as the third category because of the importance the study team placed on explaining the concept of noninferiority to potential participants. Stakeholders’ narratives supporting these categories, including their recommendations for explaining them, are described in the next 3 sections and summarized in Table 3.
Several stakeholders said the differences between clinical care and research should be explained. Stakeholders emphasized that patients should be told their health is the top priority and their care will not be compromised if they choose to participate in the trial. Several also emphasized the importance of explaining to patients that, should they choose to take a study antibiotic, study staff will closely monitor their health to determine how well the study antibiotic is working and evaluate when they would be switched to an alternative, effective treatment for pneumonia, if the study antibiotic did not appear to be working (concept 1, Table 4).
Many stakeholders suggested patients should be informed that the study antibiotics are routinely used for treating pneumonia, though one is not FDA-approved for pneumonia. Several also suggested the advance consent form should state that if patients develop pneumonia, they will receive treatment regardless of whether they join the trial, and the treatment could be one of the study antibiotics or another antibiotic (that is already used as standard of care), and patients will not be given a study drug if they are not diagnosed with pneumonia.
Almost all stakeholders emphasized that patients should be informed that they were approached about trial participation because they are at high risk for pneumonia. Numerous stakeholders said that informing patients that they may not develop pneumonia, even though they were identified as being at risk and were invited to participate in an early enrollment clinical trial on pneumonia, was an essential concept to include. They also focused their narratives on describing that the consent form should emphasize that patients do not currently have pneumonia but that they could get it and describe the specific factors that place patients at risk for pneumonia.
Several stakeholders believed patients and their caregivers should be informed that early enrollment allows them to “make a plan” and “be proactive” in their research decision making, and provides an opportunity to make a decision about research participation before becoming sick. Some stakeholders said early enrollment allows patients to start study treatment earlier in the context of research than traditional consent because all decisions about research participation are made previously by the patient (concept 2, Table 4).
Most IRB representatives, investigators, and study coordinators acknowledged the difficulty of explaining noninferiority trials, and some described noninferiority trials incorrectly themselves. These stakeholders expressed concern about whether patients and caregivers would understand the concept of noninferiority. For this reason, several said the advance consent form should keep it simple in explaining the concept of noninferiority. Focus can be placed on describing the differences between the 2 study antibiotics and explaining noninferiority broadly when describing how the study antibiotics will be compared. They cautioned against including detailed design explanations, and some advised against using the word “worse” because that word could cause unwarranted concern about efficacy and the purpose of the trial.
Patients and caregivers said the explanation of how the study antibiotics are compared should focus on describing potential differences in efficacy, using words such as “about the same” or “better,” and the potential for the comparison to reveal important differences in adverse effects (concept 3, Table 4).
Several narratives demonstrated the struggle that some investigators, study coordinators, and IRB representatives had in finding an accurate description of a noninferiority hypothesis while balancing being true to the noninferiority hypothesis, avoiding unnecessary concern among potential study participants who believe they will receive an inferior drug, and acknowledging that the study antibiotics are currently used to treat pneumonia. For some, and because of misunderstanding by others, this struggle led to alternative suggestions to explain how the study drugs will be compared, such as “better,” “equivalent or similar,” “work equally well,” or “are similar within a certain range.”
eAppendix 2 in the Supplement includes frequency data from the first online survey. Most stakeholders rated almost all statements (n = 39) as “important, remain as is” or “important, but changes needed.” For statements rated as “important, but changes needed,” stakeholders suggested alternative wording for some statements and sought clarity for other statements. Some stakeholders suggested that certain sentences be removed from the consent text. For example, 12 stakeholders suggested removing the following statement about noninferiority trials: “Before this trial started, researchers determined how much less well the new drug can work compared to the existing drug and still be acceptable” Some stakeholders commented that information about noninferiority will be confusing, could scare participants, and is too detailed for a consent form. As a result of all stakeholders’ suggestions, we modified many of the sentences and removed some sentences. eAppendix 3 in the Supplement shows the revised text.
eAppendix 4 in the Supplement includes frequency data from the second online survey. All statements (n = 38) in the revised consent text reached at least 80% consensus for “important, should remain;” 84% (n = 32) of statements reached 90% agreement. Stakeholders recommended minor edits and made a few suggestions to remove sentences, primarily to avoid repetition. Statements describing noninferiority continued to be more problematic than other categories: the percentage of statements that reached at least 90% consensus for “important, should remain” was 91% for rationale for advance consent and early enrollment, 100% for reassurances, and 74% for noninferiority. eAppendix 3 in the Supplement shows the revised final consent text.
The previous CTTI study reported that an early enrollment strategy using advance consent is an acceptable approach to patients and other key stakeholders in clinical research.9 However, the approach places novel demands on the informed consent process, particularly for a noninferiority HABP/VABP clinical trial evaluating 2 commonly prescribed antibiotics. To address this challenge, we interviewed 52 key stakeholders to identify information they would include in consent forms given this context and how to describe this information. As may be expected, stakeholders focused on providing information about the study antibiotics and the rationale for early enrollment.
Stakeholders’ comments about reassuring patients that their clinical care takes precedence over research, while an overall research ethics principle, highlights the importance of explaining in ways meaningful to potential participants how decisions about patient care are made when research is embedded in standard care settings. Consent information must also emphasize that immediate treatment will be provided regardless of research participation, so that patients will not believe that participating in research is advantageous over standard care. While such reassurances are not unique to early enrollment, they are especially important when discussing a potential serious complication such as HABP/VABP. Thus, it is imperative to reassure patients that their care will not be compromised for the purposes of facilitating research. Such information is typically not described in detail in consent forms using suggestions from key stakeholders.
Patients who are approached about trial participation before they develop the condition of interest, in this case HABP/VABP, are expected to be at higher risk for the condition, because early enrollment works best when it focuses on patients most likely to become eligible. However, informing patients about their increased risk poses a dilemma. Patients may appreciate learning their risk and the steps being taken to reduce it, but they may also experience greater anxiety from learning about a complication they had not previously considered. For this reason, researchers using advance consent, particularly for serious conditions, may wish to identify mechanisms to help patients cope with any anxiety they experience after learning of their increased risk.
A 2017 study reported that most clinical trials of infectious disease therapeutics are noninferiority trials,8 which allow for some loss of efficacy in the new intervention compared to older, effective standards of care in trade-off for another benefit, such as decreased adverse effects or cost.13 While we refer to studies that contain noninferiority hypotheses as “noninferiority trials,” the inherent trade-off means that trials with noninferiority hypotheses should also have superiority hypotheses associated with proposed non-efficacy benefits, such as decreases in adverse effects. Hypothesized superiority of non-efficacy benefits is necessary to justify the choice of the noninferiority hypothesis and to explain the proposed trade-off between potential lesser efficacy and non-efficacy benefits. In our example, we posed that meropenem might have fewer adverse events than imipenem in trade-off for a potential loss of effect.
Researchers have described the need for different informed consent language for noninferiority trials.14 Yet, multiple interpretations of the basic principles of noninferiority remain,15 as suggested in our results. While there were concerns by stakeholders that patients might not understand the noninferiority concept, some investigators, study coordinators, and IRB members also had their own misconceptions. Others have documented a lack of varied understandings of noninferiority trials, including the trade-offs.16 We also found that whether and how to explain a noninferiority trial in consent text eludes easy consensus. Ultimately, this confusion and concern might reflect that the noninferiority design is not an intuitive statistical or clinical concept, whereas superiority designs are likely more readily understandable or more familiar. Nevertheless, inscrutability cannot be the rationale for not explaining important trial design aspects to potential participants, as explaining the study purpose is required by ethics guidelines (45 CFR 46.116).12 Consent text should emphasize the potential trade-offs between antibiotic efficacy and other benefits, acknowledging that a trial result of lesser efficacy may be considered a successful outcome. Others are engaging patients in the selection of noninferiority margins and the inherent trade-offs in these trials.17
The strengths of our study include input from diverse stakeholders and a use of an iterative process for soliciting and incorporating their feedback. Other researchers have reported the need for patient input in designing clinical trials.17 Although the proposed consent language was developed for a HABP/VABP trial, the language can be adapted for other noninferiority trials and trials using an early enrollment strategy.
Our study also has limitations. First, we used purposive sampling to select patients similar to those enrolled in HABP/VABP trials, and their opinions may not be the same as other patient populations, particularly given that many of these stakeholders had high levels of education. Second, we did not evaluate the final proposed consent language after the second online survey. Further research can assess the utility of this language with a larger number of stakeholders, including how best to modify the language for non-US populations. We do not intend, however, for the proposed language to be used verbatim in all situations. Rather, we hope the language will inform researchers’ decisions about the kinds of information to include in consent documents and provide sample text that is acceptable to many stakeholders. Third, we were guided by stakeholders’ statements but made necessarily subjective judgments about what to include and how to phrase the statements. Fourth, we explained early enrollment and noninferiority (for some stakeholders) at the beginning of the qualitative interview, which may have informed stakeholders’ suggestions for topics to include in the consent text. Fifth, consent text for other noninferiority trials will change based on the hypothesized non-efficacy benefits proposed with the new intervention.
Adding language to already lengthy consent forms may be undesirable. However, every sentence in the final consent text was rated as “important, should remain” by most stakeholders. We envision that this sample language will replace some current sections of consent forms while providing greater clarity on study purpose and potential harms and benefits for potential study participants, which is a goal of informed consent.
We used data-driven input from key stakeholders to generate proposed consent language for noninferiority trials using an early enrollment strategy. The proposed consent language, in combination with a strategy for enrolling patients at highest risk for pneumonia, may help potential participants make informed decisions about their involvement in the clinical research and improve enrollment rates that are necessary to evaluate new treatments and improve patient care.
Accepted for Publication: March 18, 2020.
Published: May 22, 2020. doi:10.1001/jamanetworkopen.2020.5435
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Corneli A et al. JAMA Network Open.
Corresponding Author: Amy Corneli, PhD, Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC 27701 (firstname.lastname@example.org).
Author Contributions: Dr Corneli had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Corneli, Calvert, Powers, Collyar, Perry, Farley, Santiago, Donnelly, Fowler, Holland.
Acquisition, analysis, or interpretation of data: Corneli, Swezey, Perry, Donnelly, De Anda, Blanchard, Fowler, Holland.
Drafting of the manuscript: Corneli, Calvert, Powers, Collyar, Perry, Donnelly, Blanchard, Holland.
Critical revision of the manuscript for important intellectual content: Corneli, Calvert, Swezey, Perry, Farley, Santiago, De Anda, Fowler, Holland.
Statistical analysis: Corneli, Swezey, Perry.
Obtained funding: Farley, Santiago, Fowler.
Administrative, technical, or material support: Corneli, Perry, Santiago, De Anda, Blanchard.
Supervision: Corneli, Powers, Collyar, Fowler, Holland.
Conflict of Interest Disclosures: Dr Powers reports consulting for Corbus, Eli Lilly, Fuji, Gilead, Johnson & Johnson, Microbion, Otsuka, and Romark. Dr Fowler reports personal fees from Novartis, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Basilea, Affinergy, Janssen, xBiotech, Contrafect, Regeneron, Basilea, Destiny, Amphliphi Biosciences, Integrated Biotherapeutics; C3J, grants from NIH, MedImmune, Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Cubist/Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius; Genentech, Regeneron, Basilea, Janssen, from Green Cross, Cubist, Cerexa, Durata, Theravance; Debiopharm, Royalties from UpToDate; personal fees from Arrevus, DaVolterra, Eicos, GlaxoSmithKline, and Shinogi outside the submitted work; and a patent sepsis diagnostics pending. Dr Holland reports consulting for Basilea Pharmaceutica, Motif Bio, Genentech, and Theravance; and serving on a scientific advisory board for Motif Bio. Dr Calvert reported grants from U.S. FDA and other from CTTI Member Organizations during the conduct of the study. Dr Swezey reported grants from U.S. Food and Drug Administration and other from Annual fees from CTTI Member Organizations during the conduct of the study. Dr Collyar reported personal fees from CTTI during the conduct of the study; personal fees and non-financial support from Parexel, personal fees and non-financial support from Merck, non-financial support from Voz Advisors, personal fees and non-financial support from M2GEN, non-financial support from McKinsey & Associates, personal fees from BridgeBio, non-financial support from Boehringer Ingelheim, other support from Novartis, Janssen, Takeda, Incyte, and Odonate; and personal fees and nonfinancial support from IQVIA and nonfinancial support from TrialScope outside the submitted work. Dr De Anda reported other support from Merck & Co, Inc, during the conduct of the study, and from Merck & Co, Inc outside the submitted work. Dr Holland reported other support from Clinical Trials Transformation Initiative during the conduct of the study; personal fees from Basilea Pharmaceutica, Genentech, Motif Bio, Theravance, and Roivant Sciences outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported by grant R18FD005292 from the US Food and Drug Administration (FDA) and by pooled membership fees from the Clinical Trials Transformation Initiative’s (CTTI) member organizations.
Role of the Funder/Sponsor: The FDA and CTTI membership fees funded the study; members of the both the FDA and CTTI were part of the study team. The funders/sponsors contributed to the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: Views expressed in this publication do not necessarily reflect the official policies of the Department of Health and Human Services, nor does any mention of trade names, commercial practices, or organization imply endorsement by the US government.
Meeting Presentation: Portions of this paper were presented at the PRIM&R Advancing Ethical Research Conference; November 6, 2017; San Antonio, Texas.
Additional Contributions: Damon M. Seils, MA, Duke University, provided editorial assistance. He was compensated as part of his salary.
Create a personal account or sign in to: